Eterna Therapeutics Stock Forward View
| ERNA Stock | USD 0.35 0.33 49.07% |
Eterna Stock outlook is based on your current time horizon. Investors can use this forecasting interface to forecast Eterna Therapeutics stock prices and determine the direction of Eterna Therapeutics's future trends based on various well-known forecasting models. We suggest always using this module together with an analysis of Eterna Therapeutics' historical fundamentals, such as revenue growth or operating cash flow patterns.
At this time the rsi of Eterna Therapeutics' share price is below 20 suggesting that the stock is significantly oversold. The fundamental principle of the Relative Strength Index (RSI) is to quantify the velocity at which market participants are driving the price of a financial instrument upwards or downwards. Momentum 0
Sell Peaked
Oversold | Overbought |
Wall Street Target Price 3 | Quarterly Revenue Growth (0.94) |
Using Eterna Therapeutics hype-based prediction, you can estimate the value of Eterna Therapeutics from the perspective of Eterna Therapeutics response to recently generated media hype and the effects of current headlines on its competitors.
The Naive Prediction forecasted value of Eterna Therapeutics on the next trading day is expected to be 0.32 with a mean absolute deviation of 0.06 and the sum of the absolute errors of 3.42. Eterna Therapeutics after-hype prediction price | USD 0.73 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Check out Historical Fundamental Analysis of Eterna Therapeutics to cross-verify your projections. Eterna Therapeutics Additional Predictive Modules
Most predictive techniques to examine Eterna price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Eterna using various technical indicators. When you analyze Eterna charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Eterna Therapeutics Cash Forecast
Forecasting cash, or other financial indicators, requires analysts to apply different statistical methods, techniques, and algorithms to find hidden patterns within the Eterna Therapeutics' financial statements to predict how it will affect future prices.
Cash | First Reported 2006-06-30 | Previous Quarter 4.3 M | Current Value 3 M | Quarterly Volatility 6.7 M |
Eterna Therapeutics Naive Prediction Price Forecast For the 7th of February
Given 90 days horizon, the Naive Prediction forecasted value of Eterna Therapeutics on the next trading day is expected to be 0.32 with a mean absolute deviation of 0.06, mean absolute percentage error of 0.01, and the sum of the absolute errors of 3.42.Please note that although there have been many attempts to predict Eterna Stock prices using its time series forecasting, we generally do not suggest using it to place bets in the real market. The most commonly used models for forecasting predictions are the autoregressive models, which specify that Eterna Therapeutics' next future price depends linearly on its previous prices and some stochastic term (i.e., imperfectly predictable multiplier).
Eterna Therapeutics Stock Forecast Pattern
| Backtest Eterna Therapeutics | Eterna Therapeutics Price Prediction | Research Analysis |
Eterna Therapeutics Forecasted Value
In the context of forecasting Eterna Therapeutics' Stock value on the next trading day, we examine the predictive performance of the model to find good statistically significant boundaries of downside and upside scenarios. Eterna Therapeutics' downside and upside margins for the forecasting period are 0 and 6.82, respectively. We have considered Eterna Therapeutics' daily market price to evaluate the above model's predictive performance. Remember, however, there is no scientific proof or empirical evidence that traditional linear or nonlinear forecasting models outperform artificial intelligence and frequency domain models to provide accurate forecasts consistently.
Model Predictive Factors
The below table displays some essential indicators generated by the model showing the Naive Prediction forecasting method's relative quality and the estimations of the prediction error of Eterna Therapeutics stock data series using in forecasting. Note that when a statistical model is used to represent Eterna Therapeutics stock, the representation will rarely be exact; so some information will be lost using the model to explain the process. AIC estimates the relative amount of information lost by a given model: the less information a model loses, the higher its quality.| AIC | Akaike Information Criteria | 112.8905 |
| Bias | Arithmetic mean of the errors | None |
| MAD | Mean absolute deviation | 0.0561 |
| MAPE | Mean absolute percentage error | 0.0496 |
| SAE | Sum of the absolute errors | 3.4236 |
Predictive Modules for Eterna Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Eterna Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Eterna Therapeutics After-Hype Price Density Analysis
As far as predicting the price of Eterna Therapeutics at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Eterna Therapeutics or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Eterna Therapeutics, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
Eterna Therapeutics Estimiated After-Hype Price Volatility
In the context of predicting Eterna Therapeutics' stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Eterna Therapeutics' historical news coverage. Eterna Therapeutics' after-hype downside and upside margins for the prediction period are 0.04 and 7.23, respectively. We have considered Eterna Therapeutics' daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models compare with traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Eterna Therapeutics is out of control at this time. Analysis and calculation of next after-hype price of Eterna Therapeutics is based on 3 months time horizon.
Eterna Therapeutics Stock Price Outlook Analysis
Have you ever been surprised when a price of a Company such as Eterna Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Eterna Therapeutics backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Eterna Therapeutics, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
1.27 | 6.50 | 0.04 | 0.19 | 6 Events / Month | 6 Events / Month | In about 6 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | |
0.35 | 0.73 | 7.35 |
|
Eterna Therapeutics Hype Timeline
Eterna Therapeutics is currently traded for 0.35. The entity has historical hype elasticity of -0.04, and average elasticity to hype of competition of -0.19. Eterna is estimated to increase in value after the next headline, with the price projected to jump to 0.73 or above. The average volatility of media hype impact on the company the price is over 100%. The price jump on the next news is projected to be 7.35%, whereas the daily expected return is currently at -1.27%. The volatility of related hype on Eterna Therapeutics is about 4276.32%, with the expected price after the next announcement by competition of 0.16. Given the investment horizon of 90 days the next estimated press release will be in about 6 days. Check out Historical Fundamental Analysis of Eterna Therapeutics to cross-verify your projections.Eterna Therapeutics Related Hype Analysis
Having access to credible news sources related to Eterna Therapeutics' direct competition is more important than ever and may enhance your ability to predict Eterna Therapeutics' future price movements. Getting to know how Eterna Therapeutics' peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Eterna Therapeutics may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| ADAP | Adaptimmune Therapeutics Plc | (0.01) | 6 per month | 15.04 | 0.03 | 22.82 | (18.18) | 168.52 | |
| MPLT | MapLight Therapeutics Common | (0.95) | 4 per month | 3.97 | (0.0007) | 8.39 | (7.08) | 39.27 | |
| LNAI | Lunai Bioworks | (0.12) | 6 per month | 0.00 | (0.01) | 12.62 | (8.82) | 55.92 | |
| PMN | ProMIS Neurosciences | (0.25) | 9 per month | 6.02 | 0.08 | 13.32 | (9.37) | 38.10 | |
| DWTX | Dogwood Therapeutics | 0.19 | 8 per month | 0.00 | (0.15) | 7.72 | (11.30) | 33.43 | |
| PHGE | Biomx Inc | 0.37 | 8 per month | 0.00 | (0.02) | 14.44 | (18.87) | 88.38 | |
| MBRX | Moleculin Biotech | (0.84) | 10 per month | 0.00 | (0.21) | 9.37 | (11.73) | 41.63 | |
| AEON | AEON Biopharma | (0.05) | 8 per month | 5.30 | 0.09 | 10.34 | (8.54) | 33.74 | |
| OSRH | OSR Holdings | 0.02 | 8 per month | 0.00 | (0.02) | 15.25 | (11.11) | 43.23 | |
| AEMD | Aethlon Medical | 0.12 | 10 per month | 0.00 | (0.16) | 10.51 | (10.29) | 38.52 |
Other Forecasting Options for Eterna Therapeutics
For every potential investor in Eterna, whether a beginner or expert, Eterna Therapeutics' price movement is the inherent factor that sparks whether it is viable to invest in it or hold it better. Eterna Stock price charts are filled with many 'noises.' These noises can hugely alter the decision one can make regarding investing in Eterna. Basic forecasting techniques help filter out the noise by identifying Eterna Therapeutics' price trends.Eterna Therapeutics Related Equities
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Eterna Therapeutics stock to make a market-neutral strategy. Peer analysis of Eterna Therapeutics could also be used in its relative valuation, which is a method of valuing Eterna Therapeutics by comparing valuation metrics with similar companies.
| Risk & Return | Correlation |
Eterna Therapeutics Market Strength Events
Market strength indicators help investors to evaluate how Eterna Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Eterna Therapeutics shares will generate the highest return on investment. By undertsting and applying Eterna Therapeutics stock market strength indicators, traders can identify Eterna Therapeutics entry and exit signals to maximize returns.
| Rate Of Daily Change | 0.51 | |||
| Day Median Price | 0.35 | |||
| Day Typical Price | 0.35 | |||
| Price Action Indicator | (0.17) | |||
| Period Momentum Indicator | (0.33) |
Eterna Therapeutics Risk Indicators
The analysis of Eterna Therapeutics' basic risk indicators is one of the essential steps in accurately forecasting its future price. The process involves identifying the amount of risk involved in Eterna Therapeutics' investment and either accepting that risk or mitigating it. Along with some essential techniques for forecasting eterna stock prices, we also provide a set of basic risk indicators that can assist in the individual investment decision or help in hedging the risk of your existing portfolios.
| Mean Deviation | 4.51 | |||
| Standard Deviation | 6.37 | |||
| Variance | 40.61 |
Please note, the risk measures we provide can be used independently or collectively to perform a risk assessment. When comparing two potential investments, we recommend comparing similar equities with homogenous growth potential and valuation from related markets to determine which investment holds the most risk.
Story Coverage note for Eterna Therapeutics
The number of cover stories for Eterna Therapeutics depends on current market conditions and Eterna Therapeutics' risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Eterna Therapeutics is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Eterna Therapeutics' long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Contributor Headline
Latest Perspective From Macroaxis
Eterna Therapeutics Short Properties
Eterna Therapeutics' future price predictability will typically decrease when Eterna Therapeutics' long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Eterna Therapeutics often depends not only on the future outlook of the potential Eterna Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Eterna Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 909.8 K | |
| Cash And Short Term Investments | 1.7 M |
Check out Historical Fundamental Analysis of Eterna Therapeutics to cross-verify your projections. For information on how to trade Eterna Stock refer to our How to Trade Eterna Stock guide.You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Eterna Therapeutics. Projected growth potential of Eterna fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Eterna Therapeutics assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Understanding Eterna Therapeutics requires distinguishing between market price and book value, where the latter reflects Eterna's accounting equity. The concept of intrinsic value - what Eterna Therapeutics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push Eterna Therapeutics' price substantially above or below its fundamental value.
It's important to distinguish between Eterna Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Eterna Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Eterna Therapeutics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.